Q3 2020 Sales Performance

GSK Vaccines pipeline Phase 1/2 Clostridium difficile gsk Phase 2 AS01 RSV paediatric Therapeutic chronic hepatitis B AS01) Phase 3 Shingrix immuno-compromised¹ Approved in EU, filed in US Bexsero paediatric (US) Recent Staphylococcus aureus AS01 start SAM (rabies model) Menveo liquid² MMR (US) Recent COVID-19 AS03 start Shigella¹ Rotarix liquid (PCV free³) (Clover Biopharmaceuticals) + Recent start COVID-19 (Medicago)+ AS03 Malaria (next generation)1 AS01 Recent start MenABCWY Recent start COVID-19 (Sanofi)+ RSV maternal¹ AS03 Phase 3 start Q4 2020 RSV older adults 1 AS01 1 In-license or other alliance relationship with third party 2 Menveo booster also in development 3 Porcine circovirus free formulation *GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations Note: Candidates using adjuvants are designated Phase 3 start Q1 2021 AS01 70 Commercial assets Global Health assets Lifecycle management Pandemic response 70

View entire presentation